MHRA Streamlines Contact Channels: Direct Emails Emphasised for Regulatory Queries
The MHRA has updated its contact guidance, migrating towards direct email channels for specific regulatory areas like marketing authorisations, pharmacovigilance, and licensing queries. This aims to improve response times but necessitates precise communication from industry operators.
London, United Kingdom — 18 March 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has revised its contact protocols, emphasising a more direct, email-centric approach for industry interactions. This shift, with the latest update dated 11 June 2026, aims to enhance efficiency and response times for a range of regulatory enquiries, from marketing authorisations to pharmacovigilance and manufacturing licences. Brand owners and manufacturers are now directed to specific mailboxes for new licence applications ([email protected]), variations ([email protected]), and manufacturer/wholesale dealer licensing ([email protected]), among others. This move signifies a strategic effort by the MHRA to categorise and channel incoming queries, reducing the burden on general helplines and ensuring specialised teams address specific issues.
A notable change includes the removal of direct telephone contact for Accounts Receivable and Accounts Payable since 26 April 2024, mandating email-only communication for financial matters ([email protected] and [email protected]). Furthermore, the MHRA has introduced dedicated email contacts for regulatory issues pertinent to Scotland, Wales, and Northern Ireland. This regionalisation of support reflects the nuances of devolved administrations and aims to provide more targeted guidance for companies operating across the UK.
Industry operators must rapidly adapt internal communication strategies to align with these updated MHRA channels. The directive strongly advises reviewing the specific guidance for each service area on the MHRA website to ensure the correct contact point is used, explicitly stating that selecting the appropriate contact will expedite response times. Adherence to these new protocols will be critical for maintaining timely regulatory compliance and efficient engagement with the agency.
What this means for United Kingdom
UK supplement and medicine manufacturers must update their regulatory affairs and finance departments' contact matrices immediately. Failure to use the precise MHRA email addresses for marketing authorisations, variations, or pharmacovigilance queries will result in processing delays and potential compliance breaches. Procurement and finance teams must transition all payment-related communication to email, impacting invoice reconciliation and budget forecasting. The introduction of specific regional support emails for Scotland, Wales, and Northern Ireland offers an opportunity for localised brands to streamline engagement and navigate regional regulatory differences more effectively. Proactive integration of these new channels into standard operating procedures is essential to mitigate operational friction and avoid regulatory bottlenecks, preserving market entry and compliance timelines.
What to watch next
- Monitor the MHRA website for further updates on contact protocols and the potential reintroduction of specific phone services, particularly for Accounts Receivable and Payable.
- Observe the MHRA's average response times for email-based queries across different departments, particularly for licensing and pharmacovigilance, to assess the efficacy of this streamlined approach in the coming 6-12 months.
Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.